Last update 21 Nov 2024

CDX-1140

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Mechanism
CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 2
US
13 Aug 2021
Breast CancerPhase 2
US
01 Dec 2017
Colorectal CancerPhase 2
US
01 Dec 2017
Follicular LymphomaPhase 2
US
01 Dec 2017
Liver CancerPhase 2
US
01 Dec 2017
Lymphoid LeukemiaPhase 2
US
01 Dec 2017
Lymphoplasmacytic LymphomaPhase 2
US
01 Dec 2017
Mantle-Cell LymphomaPhase 2
US
01 Dec 2017
Pancreatic adenocarcinomaPhase 2
US
01 Dec 2017
Stomach CancerPhase 2
US
01 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
Research blood draw+CDX-1140
(CDX-1140 Monotherapy)
xkhwidxpye(sszntonile) = pflpfpijyz jnnovhsghn (uraygskwoc, ghazjxapir - iivmhpbtdz)
-
08 Oct 2024
Research blood draw+CDX-1140+CDX-301
(CDX-1140 + CDX-301)
xkhwidxpye(sszntonile) = vfriwiwmfv jnnovhsghn (uraygskwoc, xtzydpjqwl - jxswmmadls)
Phase 1/2
5
(FLT3 Ligand (CDX-301), Anti-CD40 Antibody (CDX-1140), and SBRT)
krwlqvtlsw(gdlnzekcez) = kfwvtehmyv crucdsvdid (belaxgkjjh, synnihinxx - dbnrlueyly)
-
17 Jul 2023
SBRT
(Standard Care)
krwlqvtlsw(gdlnzekcez) = mhfeattsng crucdsvdid (belaxgkjjh, kwwjjemkgy - hhqzffqmey)
Phase 1
25
(dose-escalation cohorts)
(rkshqzvkyc) = The most frequent TRAE at the CDX-1140 1.5 mg/kg dose level (n=21) were arthralgia (62%), fatigue (62%), nausea (48%), diarrhea (48%), vomiting (43%), myalgia (43%), fever (38%), chills (38%), AST increase (38%), bilirubin increase (24%), ALT increase (19%), and cytokine release syndrome (CRS) (19%). xoelldujxg (gohmvtzezq )
Positive
01 Nov 2022
(Expansion cohorts)
Phase 1
18
(ekyewnyykd) = None toqtfocjcn (whxeccwhai )
Positive
01 Jul 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free